Adult Immunization

Efficacy of the RZV vaccine against herpes zoster infection remained >80% in a long-term follow-up study representing 10 years since initial immunization.

The high-dose influenza vaccines provided greater relative vaccine effectiveness/efficacy vs standard dose in a cohort of more than 45 million.

Another choice of booster may help increase follow-up vaccination among the 50% of US adults who have yet to get a first booster dose.

AAFP Board Chair Sterling Ransone, Jr, MD, encourages patients to get both shots at one visit; if they don't, he has strategies to bring them back for the one they didn't get.

AAFP Board Chair Sterling Ransone, Jr, MD, offers an Academy refresher on the annual push-back from patients that is so familiar to family medicine clinicians.

The investigational respiratory syncytial virus vaccine had an overall efficacy of 82.6% against RSV-LRTD, 94.6% against severe disease, and 94.1% in adults with comorbidities.

More than 4 in 10 US adults have either misrepresented their COVID-19 status or failed to adhere to public health measures. A new survey found out why.

Pfizer announced that the first participants have been dosed in a novel phase 3 efficacy clinical trial of its quadrivalent modified RNA influenza vaccine candidate.

ESC 2022: SARS-CoV-2 mRNA vaccines were not associated with an increased risk of worsening heart failure, venous thromboembolism, or myocarditis in a large Danish real-world study.

Pfizer announced that a single dose of the vaccine, RSVpreF, demonstrated 85.7% efficacy against severe disease, defined by ≥3 symptoms.